Anti-inflammatory Effect of Cannabidiol and Palmitoylethanolamide Containing Topical Formulation on Skin in a 12- O -Tetradecanoylphorbol-13-Acetate-Induced Dermatitis Model in Mice.
Journal
Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335
Informations de publication
Date de publication:
Historique:
pubmed:
4
3
2021
medline:
22
7
2022
entrez:
3
3
2021
Statut:
ppublish
Résumé
Chronic inflammatory skin disorders, such as atopic dermatitis, have significant disease burden worldwide. Although efficacious, the adverse effect profile of topical corticosteroids limits long-term use. As an alternative, cannabinoids have been shown to have anti-inflammatory therapeutic effects. The aim of this study was to assess the effects of a topical cannabinoid product using dermatitis mouse model. Thirty-five mice were randomized into treatment groups. 12- O -tetradecanoylphorbol-13-acetate was used as an irritant on 1 ear with the contralateral ear serving as a control. Ear edema was calipered. The test product containing 0.9% cannabidiol and palmitoylethanolamide was compared with a potent topical corticosteroid. Treatment with topical cannabinoid formulation reduced ear edema by 51.27% at 24 hours' and 65.69% at 48 hours' postapplication. Alternatively, mometasone reduced ear edema by 89.82% at 24 hours and 98.25% at 48 hours. Natural reduction (control) in ear edema was 26.32% at 24 hours and 44.21% at 48 hours. Both test groups resulted in significantly decreased edema when compared with baseline ( P < 0.05), as well as compared with the negative control group ( P < 0.05). Significant reduction in ear edema, a marker for localized cutaneous inflammation, could be attributed to anti-inflammatory properties of cannabinoids. Although effects were less robust than topical corticosteroid use, cannabinoid formulations have therapeutic promise for dermatitis.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic inflammatory skin disorders, such as atopic dermatitis, have significant disease burden worldwide. Although efficacious, the adverse effect profile of topical corticosteroids limits long-term use. As an alternative, cannabinoids have been shown to have anti-inflammatory therapeutic effects.
OBJECTIVE
OBJECTIVE
The aim of this study was to assess the effects of a topical cannabinoid product using dermatitis mouse model.
METHODS
METHODS
Thirty-five mice were randomized into treatment groups. 12- O -tetradecanoylphorbol-13-acetate was used as an irritant on 1 ear with the contralateral ear serving as a control. Ear edema was calipered. The test product containing 0.9% cannabidiol and palmitoylethanolamide was compared with a potent topical corticosteroid.
RESULTS
RESULTS
Treatment with topical cannabinoid formulation reduced ear edema by 51.27% at 24 hours' and 65.69% at 48 hours' postapplication. Alternatively, mometasone reduced ear edema by 89.82% at 24 hours and 98.25% at 48 hours. Natural reduction (control) in ear edema was 26.32% at 24 hours and 44.21% at 48 hours. Both test groups resulted in significantly decreased edema when compared with baseline ( P < 0.05), as well as compared with the negative control group ( P < 0.05).
CONCLUSIONS
CONCLUSIONS
Significant reduction in ear edema, a marker for localized cutaneous inflammation, could be attributed to anti-inflammatory properties of cannabinoids. Although effects were less robust than topical corticosteroid use, cannabinoid formulations have therapeutic promise for dermatitis.
Identifiants
pubmed: 33654018
doi: 10.1097/DER.0000000000000722
pii: 01206501-900000000-99498
doi:
Substances chimiques
Acetates
0
Amides
0
Anti-Inflammatory Agents
0
Ethanolamines
0
Palmitic Acids
0
Cannabidiol
19GBJ60SN5
palmidrol
6R8T1UDM3V
Tetradecanoylphorbol Acetate
NI40JAQ945
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-281Informations de copyright
Copyright © 2022 American Contact Dermatitis Society. All Rights Reserved.
Déclaration de conflit d'intérêts
C.W.R. is salary funded by Pfizer Independent Grants for Learning and Change (principal investigator, R.P.D.): inflammatory and immune-mediated skin disease fellowship. J. F. and H.Y. are salary funded by CQ Science. The other authors have no funding or conflicts of interest to declare.
Références
Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care 2017;23(Suppl 8):S115–S123.
Eichenfield LF, Stein Gold LF. The disease burden of atopic dermatitis. Semin Cutan Med Surg 2017;36(4S):S92–S94.
Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018;73(6):1284–1293.
Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016;8(3):181–190.
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11(5):467–474.
Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009;1(7):1333–1349.
Sangiovanni E, Fumagalli M, Pacchetti B, et al. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phytother Res 2019;33(8):2083–2093.
Caterina MJ. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci 2014;5(11):1107–1116.
Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316(5830):1494–1497.
Oláh A, Bíró T. Targeting cutaneous cannabinoid signaling in inflammation—a “high”-way to heal? EBioMedicine 2017;16:3–5.
Eagleston LRM, Kalani NK, Patel RR, et al. Cannabinoids in dermatology: a scoping review. Dermatol Online J 2018;24(6):13030/qt7pn8c0sb.
Petersen TK. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol 2006;99(2):104–115.
Bralley EE, Greenspan P, Hargrove JL, et al. Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation. J Inflamm (Lond) 2008;5:1.
National Research Council. Guide for the Care and Use of Laboratory Animals . Washington, DC: National Academy Press; 1996.
Gupta AK, Fisher GJ, Elder JT, et al. Sphingosine inhibits phorbol ester–induced inflammation, ornithine decarboxylase activity, and activation of protein kinase C in mouse skin. J Invest Dermatol 1988;91(5):486–491.
Cipolat S, Hoste E, Natsuga K, et al. Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility. Elife 2014;3:e01888.
Hirasawa N, Ohsawa Y, Ishihara K, et al. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: establishment of a modified allergic dermatitis model in mouse ear lobes by application of 12- O -tetradecanoyl phorbol 13-acetate: putative involvement of thymic stromal lymphopoietin and roles of histamine. J Pharmacol Sci 2009;110(3):245–250.
Coondoo A. The role of cytokines in the pathomechanism of cutaneous disorders. Indian J Dermatol 2012;57(2):90–96.
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153(2):199–215.
Kozela E, Juknat A, Kaushansky N, et al. Cannabinoids decrease the T H 17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 2013;8(5):1265–1276.
Sugaya M. The role of T H 17-related cytokines in atopic dermatitis. Int J Mol Sci 2020;21(4):1314.
Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 2009;122(2):83–96.
Ho WS, Barrett DA, Randall MD. ‘Entourage’ effects of N -palmitoylethanolamide and N -oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 2008;155(6):837–846.